id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
2299784_2 | Bromide intoxication secondary to pyridostigmine bromide therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"secondary\"]], \"start\": [[21]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Bromide intoxication\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"pyridostigmine bromide\"]], \"start\": [[34]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"pyridostigmine bromide\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
11886466_3 | We have recently encountered a patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke while being treated with pFVIII. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[152]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"pFVIII\"]], \"start\": [[165]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"acquired haemophilia\"]], \"start\": [[44]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"pFVIII\"]], \"start\": [[165]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke\"]], \"start\": [[31]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"thrombotic left middle cerebral artery distribution stroke\"]], \"start\": [[81]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
22735246_4 | We present a case of serotonin syndrome, which was precipitated by this medicine in a patient who had been predisposed by long-term treatment with sertraline, a selective serotonin reuptake inhibitor. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"precipitated\"]], \"start\": [[51]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"serotonin syndrome\"]], \"start\": [[21]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[84]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"long-term treatment with sertraline\"]], \"start\": [[122]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"sertraline\"]], \"start\": [[147]], \"entity_id\": [\"T11\"]}, \"Time_elapsed\": {\"text\": [[\"long-term\"]], \"start\": [[122]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
19789372_6 | Of the 15 patients treated with tizanidine and mexiletine, 4 suffered tizanidine-induced adverse effects such as drowsiness and dry mouth in the retrospective survey. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[81]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"tizanidine and mexiletine\"]], \"start\": [[32]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"tizanidine\"], [\"mexiletine\"], [\"tizanidine\"]], \"start\": [[32], [47], [70]], \"entity_id\": [\"T17\", \"T18\", \"T21\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[43]], \"entity_id\": [\"T19\"]}, \"Drug\": {\"text\": [[\"tizanidine\"], [\"mexiletine\"]], \"start\": [[32], [47]], \"entity_id\": [\"T17\", \"T18\"]}}]}, \"Effect\": {\"text\": [[\"drowsiness and dry mouth\"]], \"start\": [[113]], \"entity_id\": [\"T15\"]}, \"Subject\": {\"text\": [[\"15 patients\"], [\"4\"]], \"start\": [[7], [59]], \"entity_id\": [\"T12\", \"T20\"], \"Population\": {\"text\": [[\"15\"]], \"start\": [[7]], \"entity_id\": [\"T16\"]}}}"
}
]
}
] |
2006943_1 | Type I second-degree AV block (Mobitz type I, Wenckebach AV block) during ritodrine therapy for preterm labor. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[67]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Type I second-degree AV block (Mobitz type I, Wenckebach AV block)\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"ritodrine\"]], \"start\": [[74]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"preterm labor\"]], \"start\": [[96]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"ritodrine\"]], \"start\": [[74]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
20412003_1 | After other potential causes of liver toxicity were excluded, TMP-SMX was determined to be the cause of his acute liver toxicity. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"determined\"]], \"start\": [[74]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"TMP-SMX\"]], \"start\": [[62]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"TMP\"], [\"SMX\"]], \"start\": [[62], [66]], \"entity_id\": [\"T8\", \"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"-\"]], \"start\": [[65]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"TMP\"], [\"SMX\"]], \"start\": [[62], [66]], \"entity_id\": [\"T8\", \"T9\"]}}]}, \"Effect\": {\"text\": [[\"acute liver toxicity\"]], \"start\": [[108]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
6149250_3 | One of the patients had a dexamethasone dependent brain metastatic condition. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"had\"]], \"start\": [[20]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"One of the patients\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Population\": {\"text\": [[\"One\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"dexamethasone\"]], \"start\": [[26]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"dexamethasone\"]], \"start\": [[26]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"brain metastatic condition\"]], \"start\": [[50]], \"entity_id\": [\"T5\"]}}, \"Effect\": {\"text\": [[\"brain metastatic condition\"]], \"start\": [[50]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
12365708_2 | Biomicroscopy revealed amiodarone corneal deposits. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"revealed\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Biomicroscopy\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Biomicroscopy\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"amiodarone corneal deposits\"]], \"start\": [[23]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
14601701_5 | This case and a review of the literature show the severe and unpredictable nature of ethambutol toxicity and its potential for irreversible vision loss despite careful ophthalmologic monitoring. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"unpredictable\"]], \"start\": [[61]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"ethambutol\"]], \"start\": [[85]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"ethambutol\"]], \"start\": [[85]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"irreversible vision loss\"]], \"start\": [[127]], \"entity_id\": [\"T9\"]}, \"Speculated\": {\"text\": [[\"potential\"]], \"start\": [[113]], \"entity_id\": [\"T12\"], \"value\": true}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[50]], \"entity_id\": [\"T14\"], \"value\": \"High\"}}"
}
]
}
] |
15790469_4 | Recently, some studies have also reported association between patients with juvenile rheumatoid arthritis (JRA) treated with Methotrexate (MTX) and malignant lymphoma developing. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"association\"]], \"start\": [[42]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Methotrexate (MTX)\"]], \"start\": [[125]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"Methotrexate\"]], \"start\": [[125]], \"entity_id\": [\"T16\"]}, \"Disorder\": {\"text\": [[\"juvenile rheumatoid arthritis\"]], \"start\": [[76]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"malignant lymphoma\"]], \"start\": [[148]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"patients with juvenile rheumatoid arthritis (JRA\"]], \"start\": [[62]], \"entity_id\": [\"T12\"]}}"
}
]
}
] |
10679548_6 | The two middle aged women presented with respiratory symptoms after prolonged treatment with nitrofurantoin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presented\"]], \"start\": [[26]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"The two middle aged women\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[4]], \"entity_id\": [\"T7\"]}, \"Age\": {\"text\": [[\"middle aged\"]], \"start\": [[8]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"women\"]], \"start\": [[20]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"respiratory symptoms\"]], \"start\": [[41]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"prolonged treatment with nitrofurantoin\"]], \"start\": [[68]], \"entity_id\": [\"T6\"], \"Freq\": {\"text\": [[\"prolonged treatment\"]], \"start\": [[68]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"nitrofurantoin\"]], \"start\": [[93]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
20378385_1 | OBJECTIVE: 1) To describe a patient with rheumatoid arthritis receiving adalimumab who developed fever, pancytopenia, splenomegaly, and extreme hyperferritinemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[87]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"fever, pancytopenia, splenomegaly, and extreme hyperferritinemia\"]], \"start\": [[97]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"a patient with rheumatoid arthritis\"]], \"start\": [[26]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"rheumatoid arthritis\"]], \"start\": [[41]], \"entity_id\": [\"T13\"]}}, \"Treatment\": {\"text\": [[\"adalimumab\"]], \"start\": [[72]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"adalimumab\"]], \"start\": [[72]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
12523465_2 | Visual hallucinations associated with zonisamide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated with\"]], \"start\": [[22]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Visual hallucinations\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"zonisamide\"]], \"start\": [[38]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"zonisamide\"]], \"start\": [[38]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
8667442_1 | Milk-alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[21]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Milk-alkali syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"1,25(OH)2D\"]], \"start\": [[32]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"1,25(OH)2D\"]], \"start\": [[32]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"hypoparathyroidism\"]], \"start\": [[61]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"a patient with hypoparathyroidism.\"]], \"start\": [[46]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
10494874_1 | We report the case of a female acromegalic patient in whom multiple hepatic adenomas appeared soon after danazol treatment for uterine fibromatosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"appeared\"]], \"start\": [[85]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a female acromegalic patient\"]], \"start\": [[22]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"acromegalic\"]], \"start\": [[31]], \"entity_id\": [\"T4\"]}, \"Gender\": {\"text\": [[\"female\"]], \"start\": [[24]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"hepatic adenomas\"]], \"start\": [[68]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"danazol treatment\"]], \"start\": [[105]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"uterine fibromatosis.\"]], \"start\": [[127]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"danazol\"]], \"start\": [[105]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
9347384_1 | Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[23]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"psychiatric patients\"]], \"start\": [[69]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"psychiatric\"]], \"start\": [[69]], \"entity_id\": [\"T5\"]}}, \"Effect\": {\"text\": [[\"Carbamazepine toxicity\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"clarithromycin\"]], \"start\": [[34]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"clarithromycin\"], [\"Carbamazepine\"]], \"start\": [[34], [0]], \"entity_id\": [\"T9\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"coadministration\"]], \"start\": [[49]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"clarithromycin\"], [\"Carbamazepine\"]], \"start\": [[34], [0]], \"entity_id\": [\"T9\", \"T11\"]}}]}}"
}
]
}
] |
2116935_2 | Thrombolytic therapy with tissue plasminogen activator (tPA) for acute myocardial infarction may result in major bleeding complications such as gastrointestinal or intracranial bleeding. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"result\"]], \"start\": [[97]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"tissue plasminogen activator\"]], \"start\": [[26]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"acute myocardial infarction\"]], \"start\": [[65]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"tissue plasminogen activator\"]], \"start\": [[26]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"gastrointestinal or intracranial bleeding\"]], \"start\": [[144]], \"entity_id\": [\"T14\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[93]], \"entity_id\": [\"T13\"], \"value\": true}}"
}
]
}
] |
16968538_8 | CONCLUSION: The hemolytic-uremic syndrome may be a rare complication of oxaliplatin-based chemotherapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[56]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"hemolytic-uremic syndrome\"]], \"start\": [[16]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"oxaliplatin-based chemotherapy\"]], \"start\": [[72]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"oxaliplatin\"]], \"start\": [[72]], \"entity_id\": [\"T10\"]}, \"Route\": {\"text\": [[\"chemotherapy\"]], \"start\": [[90]], \"entity_id\": [\"T11\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[42]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
10897389_1 | However, recurrent staphylococcus aureus sepsis developed during CyA therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[48]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"CyA therapy\"]], \"start\": [[65]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"CyA\"]], \"start\": [[65]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"staphylococcus aureus sepsis\"]], \"start\": [[19]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
8570441_1 | Nabumetone-associated interstitial nephritis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[11]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Nabumetone\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Nabumetone\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"interstitial nephritis\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
18362995_1 | A short review on imatinib-related hepatotoxicity is also presented. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[27]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"imatinib\"]], \"start\": [[18]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"imatinib\"]], \"start\": [[18]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hepatotoxicity\"]], \"start\": [[35]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
17260498_1 | Fatal interstitial pneumonitis associated with docetaxel administration in a patient with hormone-refractory prostate cancer. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[31]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Fatal interstitial pneumonitis\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"docetaxel\"]], \"start\": [[47]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"docetaxel\"]], \"start\": [[47]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"hormone-refractory prostate cancer\"]], \"start\": [[90]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"a patient with hormone-refractory prostate cancer\"]], \"start\": [[75]], \"entity_id\": [\"T9\"]}, \"Severity\": {\"text\": [[\"Fatal\"]], \"start\": [[0]], \"entity_id\": [\"T11\"], \"value\": \"High\"}}"
}
]
}
] |
17364199_2 | BACKGROUND: Etanercept is a tumor necrosis factor (TNF) inhibitor that has been licensed in the United States for the treatment of adult and juvenile rheumatoid arthritis as well as psoriatic arthritis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"licensed\"]], \"start\": [[80]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"Etanercept\", \"a tumor necrosis factor (TNF) inhibitor\"]], \"start\": [[12, 26]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"Etanercept\"]], \"start\": [[12]], \"entity_id\": [\"T15\"]}, \"Disorder\": {\"text\": [[\"adult and juvenile rheumatoid arthritis\"], [\"psoriatic arthritis\"]], \"start\": [[131], [182]], \"entity_id\": [\"T16\", \"T17\"]}}, \"Subject\": {\"text\": [[\"adult and juvenile rheumatoid arthritis as well as psoriatic arthritis\"]], \"start\": [[131]], \"entity_id\": [\"T9\"], \"Age\": {\"text\": [[\"adult\"], [\"juvenile\"]], \"start\": [[131], [141]], \"entity_id\": [\"T11\", \"T12\"]}}}"
}
]
}
] |
3379435_2 | Reye-like syndrome following treatment with the pantothenic acid antagonist, calcium hopantenate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[19]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Reye-like syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"calcium hopantenate\"]], \"start\": [[77]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"calcium hopantenate\"]], \"start\": [[77]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
834512_1 | Sudden death in an infant from methemoglobinemia after administration of "sweet spirits of nitre". | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[49]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Sudden death\", \"methemoglobinemia\"]], \"start\": [[0, 31]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"an infant\"]], \"start\": [[16]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"infant\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"sweet spirits of nitre\"]], \"start\": [[74]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"sweet spirits of nitre\"]], \"start\": [[74]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
8691927_2 | FINDINGS: Six children with growth retardation noted after treatment with high-dose fluticasone propionate were found to have adrenal suppression. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"have\"]], \"start\": [[121]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"Six children with growth retardation\"]], \"start\": [[10]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"Six\"]], \"start\": [[10]], \"entity_id\": [\"T10\"]}, \"Age\": {\"text\": [[\"children\"]], \"start\": [[14]], \"entity_id\": [\"T11\"]}}, \"Treatment\": {\"text\": [[\"high-dose fluticasone propionate\"]], \"start\": [[74]], \"entity_id\": [\"T7\"], \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[74]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"fluticasone propionate\"]], \"start\": [[84]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"growth retardation\"]], \"start\": [[28]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"adrenal suppression\"]], \"start\": [[126]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
16326413_3 | Methotrexate-associated nephropathy is a rare complication in pediatric oncology, and a review of the literature suggests that exposure to nephrotoxic agents may be a significant but perhaps underrecognized risk factor for its development. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[13]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Methotrexate\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Methotrexate\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"nephropathy\"]], \"start\": [[24]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"may\"], [\"rare\"]], \"start\": [[158], [41]], \"entity_id\": [\"T7\", \"T8\"], \"value\": true}}"
}
]
}
] |
7428724_1 | Four cases of oesophageal damage associated with ingestion of the urinary anti-spasmodic agent emepronium bromide are described. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[33]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"Four cases\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"Four\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"oesophageal damage\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"ingestion of the urinary anti-spasmodic agent emepronium bromide\"]], \"start\": [[49]], \"entity_id\": [\"T6\"], \"Route\": {\"text\": [[\"ingestion\"]], \"start\": [[49]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"emepronium bromide\"]], \"start\": [[95]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
10555917_1 | A 66-year-old Japanese woman with severe scleroderma developed anemia and thrombocytopenia due to D-penicillamine (D-Pen) treatment, although the leukopenia was not markedly severe. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[53]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"A 66-year-old Japanese woman with severe scleroderma\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"66-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T11\"]}, \"Race\": {\"text\": [[\"Japanese\"]], \"start\": [[14]], \"entity_id\": [\"T12\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[23]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"anemia and thrombocytopenia\"]], \"start\": [[63]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"D-penicillamine (D-Pen) treatment\"]], \"start\": [[98]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"severe scleroderma\"]], \"start\": [[34]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"D-penicillamine\"]], \"start\": [[98]], \"entity_id\": [\"T15\"]}}}"
}
]
}
] |
20456080_4 | Corticosteroid injections are commonly used as effective treatments for a variety of pain disorders. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatments\"]], \"start\": [[57]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Corticosteroid injections\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Corticosteroid\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"injections\"]], \"start\": [[15]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"pain disorders\"]], \"start\": [[85]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
15549981_1 | We present two cases of anaphylaxis under anaesthesia where return of spontaneous circulation was refractory to epinephrine, but occurred following the administration of the alpha-agonist metaraminol. | true | [
{
"events": [
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"occurred\"]], \"start\": [[129]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"epinephrine\", \"administration of the alpha-agonist metaraminol\"]], \"start\": [[112, 152]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"anaphylaxis under anaesthesia\"]], \"start\": [[24]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"metaraminol\"], [\"epinephrine\"]], \"start\": [[188], [112]], \"entity_id\": [\"T6\", \"T7\"]}, \"Combination\": [{\"event_id\": \"E1\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"administration\"]], \"start\": [[152]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"epinephrine\"], [\"metaraminol\"]], \"start\": [[112], [188]], \"entity_id\": [\"T7\", \"T6\"]}}]}, \"Effect\": {\"text\": [[\"return of spontaneous circulation\"]], \"start\": [[60]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
3310776_1 | A 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed attacks of asthma when captopril was added to the nadolol and dyazide treatment for his high blood pressure. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[111]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"A 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"51-yr-old\"]], \"start\": [[2]], \"entity_id\": [\"T10\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[23]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"attacks of asthma\"]], \"start\": [[121]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"captopril was added to the nadolol and dyazide\"]], \"start\": [[144]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"high blood pressure\"]], \"start\": [[209]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"captopril\"], [\"nadolol\"], [\"dyazide\"]], \"start\": [[144], [171], [183]], \"entity_id\": [\"T13\", \"T14\", \"T15\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"added\"]], \"start\": [[158]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"captopril\"], [\"nadolol\"], [\"dyazide\"]], \"start\": [[144], [171], [183]], \"entity_id\": [\"T13\", \"T14\", \"T15\"]}}]}}"
}
]
}
] |
9876809_5 | After ticlopidine was discontinued, the patient was rechallenged with the same dose of phenytoin without symptoms of toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"toxicity\"]], \"start\": [[117]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"toxicity\"]], \"start\": [[117]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"After ticlopidine was discontinued\", \"rechallenged with the same dose of phenytoin\"]], \"start\": [[0, 52]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"ticlopidine\"], [\"phenytoin\"]], \"start\": [[6], [87]], \"entity_id\": [\"T6\", \"T11\"]}}, \"Negated\": {\"text\": [[\"without\"]], \"start\": [[97]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
19151423_1 | Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[15]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Rhabdomyolysis\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"interaction of ciprofloxacin with simvastatin\"]], \"start\": [[34]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"ciprofloxacin\"], [\"simvastatin\"]], \"start\": [[49], [68]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[34]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"ciprofloxacin\"], [\"simvastatin\"]], \"start\": [[49], [68]], \"entity_id\": [\"T10\", \"T11\"]}}]}}"
}
]
}
] |
8672829_1 | After receiving 3 doses of ifosfamide/mesna, she was found to be unresponsive. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"found\"]], \"start\": [[53]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"ifosfamide/mesna\"]], \"start\": [[27]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"ifosfamide\"], [\"mesna\"]], \"start\": [[27], [38]], \"entity_id\": [\"T7\", \"T8\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"/\"]], \"start\": [[37]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"ifosfamide\"], [\"mesna\"]], \"start\": [[27], [38]], \"entity_id\": [\"T7\", \"T8\"]}}]}, \"Effect\": {\"text\": [[\"unresponsive\"]], \"start\": [[65]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"she\"]], \"start\": [[45]], \"entity_id\": [\"T9\"], \"Gender\": {\"text\": [[\"she\"]], \"start\": [[45]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
2316232_2 | Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"secondary to\"]], \"start\": [[25]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Symptomatic hypoglycemia\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"glipizide-trimethoprim/sulfamethoxazole drug interaction\"]], \"start\": [[40]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"glipizide\"], [\"trimethoprim\"], [\"sulfamethoxazole\"]], \"start\": [[40], [50], [63]], \"entity_id\": [\"T8\", \"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[85]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"glipizide\"], [\"trimethoprim\"], [\"sulfamethoxazole\"]], \"start\": [[40], [50], [63]], \"entity_id\": [\"T8\", \"T9\", \"T10\"]}}]}}"
}
]
}
] |
18421192_1 | A 51-year-old man developed type 1 diabetes mellitus following 24 weeks of treatment with recombinant alpha-2b peginterferon plus ribavirin for chronic hepatitis C. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[18]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"A 51-year-old man\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"51-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[14]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"type 1 diabetes mellitus\"]], \"start\": [[28]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"24 weeks of treatment with recombinant alpha-2b peginterferon plus ribavirin\"]], \"start\": [[63]], \"entity_id\": [\"T7\"], \"Time_elapsed\": {\"text\": [[\"24 weeks\"]], \"start\": [[63]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"recombinant alpha-2b peginterferon\"], [\"ribavirin\"]], \"start\": [[90], [130]], \"entity_id\": [\"T11\", \"T12\"]}, \"Disorder\": {\"text\": [[\"chronic hepatitis C\"]], \"start\": [[144]], \"entity_id\": [\"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"plus\"]], \"start\": [[125]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"recombinant alpha-2b peginterferon\"], [\"ribavirin\"]], \"start\": [[90], [130]], \"entity_id\": [\"T11\", \"T12\"]}}]}}"
}
]
}
] |
8832451_1 | A noninvasive method in the differential diagnosis of vecuronium-induced and magnesium-induced protracted neuromuscular block in a severely preeclamptic patient. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[65]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"vecuronium\"]], \"start\": [[54]], \"entity_id\": [\"T1\"], \"Drug\": {\"text\": [[\"vecuronium\"]], \"start\": [[54]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"protracted neuromuscular block\"]], \"start\": [[95]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"severely preeclamptic patient\"]], \"start\": [[131]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"severely preeclamptic\"]], \"start\": [[131]], \"entity_id\": [\"T8\"]}}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[87]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"protracted neuromuscular block\"]], \"start\": [[95]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"severely preeclamptic patient\"]], \"start\": [[131]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"severely preeclamptic\"]], \"start\": [[131]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"magnesium\"]], \"start\": [[77]], \"entity_id\": [\"T2\"], \"Drug\": {\"text\": [[\"magnesium\"]], \"start\": [[77]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
3725284_1 | Paroxysmal supraventricular tachycardia during treatment with cisplatin and etoposide combination. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[40]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Paroxysmal supraventricular tachycardia\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"cisplatin and etoposide combination\"]], \"start\": [[62]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"cisplatin\"], [\"etoposide\"]], \"start\": [[62], [76]], \"entity_id\": [\"T7\", \"T8\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[86]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"etoposide\"], [\"cisplatin\"]], \"start\": [[76], [62]], \"entity_id\": [\"T8\", \"T7\"]}}]}}"
}
]
}
] |
424824_1 | Conversely, diffuse interstitial pulmonary fibrosis should be considered in the differential diagnosis of patients receiving methotrexate who develop bilateral pulmonary infiltrates seen on chest roentgenograms. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"develop\"]], \"start\": [[142]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"methotrexate\"]], \"start\": [[125]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[125]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"diffuse interstitial pulmonary fibrosis\", \"bilateral pulmonary infiltrates\"]], \"start\": [[12, 150]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[106]], \"entity_id\": [\"T8\"]}, \"Speculated\": {\"text\": [[\"should be considered\"]], \"start\": [[52]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
2316232_1 | An 83-year-old man receiving glipizide 10 mg bid developed symptomatic hypoglycemia within three days of adding trimethoprim/sulfamethoxazole (TMP/SMX) to his regimen. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[49]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"symptomatic hypoglycemia\"]], \"start\": [[59]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"receiving glipizide 10 mg\", \"three days of adding trimethoprim/sulfamethoxazole (TMP/SMX)\"]], \"start\": [[19, 91]], \"entity_id\": [\"T11\"], \"Time_elapsed\": {\"text\": [[\"three days\"]], \"start\": [[91]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"trimethoprim\"], [\"sulfamethoxazole\"], [\"glipizide\"]], \"start\": [[112], [125], [29]], \"entity_id\": [\"T14\", \"T15\", \"T16\"]}, \"Dosage\": {\"text\": [[\"10 mg\"]], \"start\": [[39]], \"entity_id\": [\"T17\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[19]], \"entity_id\": [\"T18\"]}, \"Drug\": {\"text\": [[\"glipizide\"], [\"trimethoprim\"], [\"sulfamethoxazole\"]], \"start\": [[29], [112], [125]], \"entity_id\": [\"T16\", \"T14\", \"T15\"]}}]}, \"Subject\": {\"text\": [[\"An 83-year-old man\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"83-year-old\"]], \"start\": [[3]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[15]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
16268429_1 | In this case senna was likely the cause of a subacute cholestatic hepatitis exemplifying again the potential role of herbal related liver injury. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"senna\"]], \"start\": [[13]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"senna\"]], \"start\": [[13]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"a subacute cholestatic hepatitis\", \"herbal related liver injury\"]], \"start\": [[43, 117]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"likely\"]], \"start\": [[23]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
12598508_4 | Early peritoneal dialysis has not previously been reported for lisinopril induced multiorgan failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[74]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"lisinopril\"]], \"start\": [[63]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"lisinopril\"]], \"start\": [[63]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"multiorgan failure\"]], \"start\": [[82]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
12862258_3 | Various case reports concerning dapsone-induced agranulocytosis are reviewed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[40]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"dapsone\"]], \"start\": [[32]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"dapsone\"]], \"start\": [[32]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"agranulocytosis\"]], \"start\": [[48]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
18717612_3 | We report the first case of a 54-year-old Turkish woman who presented with ceftriaxone-induced FDE. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[87]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a 54-year-old Turkish woman\"]], \"start\": [[28]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"54-year-old\"]], \"start\": [[30]], \"entity_id\": [\"T7\"]}, \"Race\": {\"text\": [[\"Turkish\"]], \"start\": [[42]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[50]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"ceftriaxone\"]], \"start\": [[75]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"ceftriaxone\"]], \"start\": [[75]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"FDE\"]], \"start\": [[95]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
10487084_1 | In all cases, seizures were controlled by withdrawal of phenytoin and reduction of drug levels. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"controlled\"]], \"start\": [[28]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"withdrawal of phenytoin and reduction of drug levels\"]], \"start\": [[42]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"phenytoin\"]], \"start\": [[56]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"seizures\"]], \"start\": [[14]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
15379082_3 | This case describes fulminant hepatic failure in a patient taking disulfiram with no previous liver disease and report of being compliant with alcohol abstinence. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[46]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"fulminant hepatic failure\"]], \"start\": [[20]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[49]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"disulfiram\"]], \"start\": [[66]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"disulfiram\"]], \"start\": [[66]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
15373932_2 | Fungal infection is a significant comorbidity in patients with diabetes mellitus, and ketoconazole, an antifungal agent, causes a number of drug interactions with coadministered drugs. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"causes\"]], \"start\": [[121]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"patients with diabetes mellitus\"]], \"start\": [[49]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"diabetes mellitus\"]], \"start\": [[63]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"ketoconazole\"]], \"start\": [[86]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"ketoconazole\"]], \"start\": [[86]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"Fungal infection\"]], \"start\": [[0]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"a number of drug interactions with coadministered drugs\"]], \"start\": [[128]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
15289139_1 | Dorzolamide-induced choroidal detachment in a surgically untreated eye. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[12]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Dorzolamide\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Dorzolamide\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"choroidal detachment\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a surgically untreated eye\"]], \"start\": [[44]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
8438851_2 | Idiosyncratic factors involving vasopressin receptor affinity and distribution, vasopressin-associated vasodilation in some vascular beds, and the effect of vasopressin on the renin-angiotensin system may further contribute to impaired tissue perfusion. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"contribute\"]], \"start\": [[213]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"vasopressin\"]], \"start\": [[32]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"vasopressin\"]], \"start\": [[32]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"impaired tissue perfusion\"]], \"start\": [[227]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
16765687_2 | Rapid resolution of topiramate-induced angle-closure glaucoma with methylprednisolone and mannitol. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"resolution\"]], \"start\": [[6]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"methylprednisolone and mannitol\"]], \"start\": [[67]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"topiramate-induced angle-closure glaucoma\"]], \"start\": [[20]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"methylprednisolone\"], [\"mannitol\"]], \"start\": [[67], [90]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[86]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"methylprednisolone\"], [\"mannitol\"]], \"start\": [[67], [90]], \"entity_id\": [\"T9\", \"T10\"]}}]}}"
},
{
"event_id": "E3",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E3\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[31]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"topiramate\"]], \"start\": [[20]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"topiramate\"]], \"start\": [[20]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"angle-closure glaucoma\"]], \"start\": [[39]], \"entity_id\": [\"T14\"]}}"
}
]
}
] |
7098384_1 | A 66-year-old mand suffering from severe coronary heart disease took digoxin with suicidal intent an was treated for the ensuing complete atrioventricular block with digoxin-specific antibody fragments. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"took\"]], \"start\": [[64]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"A 66-year-old mand suffering from severe coronary heart disease\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"66-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"mand\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"coronary heart diseas\"]], \"start\": [[41]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"digoxin\"]], \"start\": [[69]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"digoxin\"]], \"start\": [[69]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"complete atrioventricular block\"]], \"start\": [[129]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
16116136_1 | A patient with generalized MG was effectively managed with MM but developed CNS lymphoma after 3 years of treatment. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"managed\"]], \"start\": [[46]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"MM\"]], \"start\": [[59]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"generalized MG\"]], \"start\": [[15]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"MM\"]], \"start\": [[59]], \"entity_id\": [\"T7\"]}}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[66]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"A patient with generalized MG\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"MM\"]], \"start\": [[59]], \"entity_id\": [\"T13\"], \"Duration\": {\"text\": [[\"3 years\"]], \"start\": [[95]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"CNS lymphoma\"]], \"start\": [[76]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
12114387_1 | Epoprostenol may be associated rarely with severe erythroderma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[20]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Epoprostenol\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Epoprostenol\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"severe erythroderma.\"]], \"start\": [[43]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[13]], \"entity_id\": [\"T4\"], \"value\": true}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[43]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
15533031_2 | We report the case of a patient with increased cerebral cortical excitability following intoxication with flupirtine, a centrally acting analgesic and antispastic drug. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[78]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[22]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"increased cerebral cortical excitability\"]], \"start\": [[37]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"flupirtine\"]], \"start\": [[106]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"flupirtine\"]], \"start\": [[106]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
6702890_3 | This case represents the third example of erythroid aplasia associated with an anti-inflammatory agent and the first instance due to fenoprofen. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[60]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"fenoprofen\"]], \"start\": [[133]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"fenoprofen\"]], \"start\": [[133]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"erythroid aplasia\"]], \"start\": [[42]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
11568758_1 | Lichenoid drug eruption to salsalate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"eruption\"]], \"start\": [[15]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Lichenoid drug eruption\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"salsalate\"]], \"start\": [[27]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"salsalate\"]], \"start\": [[27]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
9211543_2 | Two pediatric oncology patients with Ewing's sarcoma and one with mixed germ cell tumor were treated with drug regimens that included bleomycin or cyclophosphamide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated with\"]], \"start\": [[93]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"drug regimens that included bleomycin or cyclophosphamide\"]], \"start\": [[106]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"bleomycin\"], [\"cyclophosphamide\"]], \"start\": [[134], [147]], \"entity_id\": [\"T12\", \"T13\"]}, \"Disorder\": {\"text\": [[\"Ewing's sarcoma\"], [\"mixed germ cell tumor\"]], \"start\": [[37], [66]], \"entity_id\": [\"T2\", \"T4\"]}}, \"Subject\": {\"text\": [[\"Two pediatric oncology patients with Ewing's sarcoma and one with mixed germ cell tumor\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"Two\"], [\"one\"]], \"start\": [[0], [57]], \"entity_id\": [\"T10\", \"T3\"]}, \"Age\": {\"text\": [[\"pediatric\"]], \"start\": [[4]], \"entity_id\": [\"T1\"]}}}"
}
]
}
] |
8375752_1 | Although retinoic acid is well tolerated by the majority of patients with this disease, a potentially fatal complication of this kind of treatment has been reported: "the retinoic acid syndrome". | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[108]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"retinoic acid\"]], \"start\": [[9]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"retinoic acid\"]], \"start\": [[9]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"fatal complication\"]], \"start\": [[102]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"potentially\"]], \"start\": [[90]], \"entity_id\": [\"T6\"], \"value\": true}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[102]], \"entity_id\": [\"T9\"], \"value\": \"Medium\"}}"
}
]
}
] |
2011096_2 | Three of 38 children given high-dose cytosine arabinoside therapy developed a previously undescribed complication. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[66]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"38 children\"]], \"start\": [[9]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"38\"]], \"start\": [[9]], \"entity_id\": [\"T9\"]}, \"Age\": {\"text\": [[\"children\"]], \"start\": [[12]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"high-dose cytosine arabinoside\"]], \"start\": [[27]], \"entity_id\": [\"T6\"], \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[27]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"cytosine arabinoside\"]], \"start\": [[37]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"complication\"]], \"start\": [[101]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
20178709_1 | A case of aseptic pleuropericarditis in a patient with chronic plaque psoriasis under methotrexate therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[37]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient with chronic plaque psoriasis\"]], \"start\": [[40]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"methotrexate therapy\"]], \"start\": [[86]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[86]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"chronic plaque psoriasis\"]], \"start\": [[55]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"aseptic pleuropericarditis\"]], \"start\": [[10]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
16207263_1 | Linezolid-induced dyserythropoiesis: chloramphenicol toxicity revisited. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[10]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Linezolid\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Linezolid\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"dyserythropoiesis\"]], \"start\": [[18]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
11328247_1 | CONCLUSION: The present findings suggest that fluvoxamine can cause increased libido in some patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[62]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"increased libido\"]], \"start\": [[68]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"some patients\"]], \"start\": [[88]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"fluvoxamine\"]], \"start\": [[46]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"fluvoxamine\"]], \"start\": [[46]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
2144305_1 | A unique case of a transient, nonpigmenting fixed drug eruption caused by the radiopaque contrast medium iothalamate is reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[64]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"iothalamate\"]], \"start\": [[105]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"iothalamate\"]], \"start\": [[105]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"a transient, nonpigmenting fixed drug eruption\"]], \"start\": [[17]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
15785053_1 | Mucosal pigmentation after oral lichen planus treatment with topical tacrolimus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[46]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Mucosal pigmentation\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"topical tacrolimus\"]], \"start\": [[61]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"oral lichen planus\"]], \"start\": [[27]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"tacrolimus\"]], \"start\": [[69]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"topical\"]], \"start\": [[61]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
10473079_2 | We now report the first known cancer patient who developed life-threatening complications after treatment with topical 5-FU and was shown subsequently to have profound DPD deficiency. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[49]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"cancer patient\"]], \"start\": [[30]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"life-threatening complications\", \"have profound DPD deficiency\"]], \"start\": [[59, 154]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"topical 5-FU\"]], \"start\": [[111]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"cancer\"]], \"start\": [[30]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"5-FU\"]], \"start\": [[119]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"topical\"]], \"start\": [[111]], \"entity_id\": [\"T12\"]}}, \"Severity\": {\"text\": [[\"life-threatening\"]], \"start\": [[59]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
110153_2 | When the acute manic state is characterized by marked psychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe lithium neurotoxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated with\"]], \"start\": [[104]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"lithium\"]], \"start\": [[173]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"lithium\"]], \"start\": [[173]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"acute manic state is characterized by marked psychotic symptoms and intense anxiety\"]], \"start\": [[9]], \"entity_id\": [\"T9\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[97]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
7781845_11 | Clinicians who manage cachectic patients, particularly those with protracted diarrhoea and/or receiving anti-malarial drugs including mefloquine, should be aware of the risk of severe hypoglycaemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"risk\"]], \"start\": [[169]], \"entity_id\": [\"T13\"]}, \"Subject\": {\"text\": [[\"cachectic patients\", \"with protracted diarrhoea\"]], \"start\": [[22, 61]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"anti-malarial drugs including mefloquine\"]], \"start\": [[104]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"mefloquine\"]], \"start\": [[134]], \"entity_id\": [\"T18\"]}, \"Disorder\": {\"text\": [[\"cachectic\"], [\"protracted diarrhoea\"]], \"start\": [[22], [66]], \"entity_id\": [\"T19\", \"T20\"]}}, \"Effect\": {\"text\": [[\"severe hypoglycaemia\"]], \"start\": [[177]], \"entity_id\": [\"T14\"]}, \"Speculated\": {\"text\": [[\"risk\"]], \"start\": [[169]], \"entity_id\": [\"T16\"], \"value\": true}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[177]], \"entity_id\": [\"T17\"], \"value\": \"Medium\"}}"
}
]
}
] |
7696938_1 | Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[50]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"amphotericin B administration\"]], \"start\": [[57]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"amphotericin B\"]], \"start\": [[57]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"Arrhythmias and cardiac arrest\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
15383642_15 | Based upon the literature review, the hypotension in this patient was possibly due to the interaction between tizanidine and lisinopril. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[79]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"the hypotension\"]], \"start\": [[34]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"the interaction between tizanidine and lisinopril\"]], \"start\": [[86]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"tizanidine\"], [\"lisinopril\"]], \"start\": [[110], [125]], \"entity_id\": [\"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[90]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"tizanidine\"], [\"lisinopril\"]], \"start\": [[110], [125]], \"entity_id\": [\"T12\", \"T13\"]}}]}, \"Subject\": {\"text\": [[\"this patient\"]], \"start\": [[53]], \"entity_id\": [\"T15\"]}, \"Speculated\": {\"text\": [[\"possibly\"]], \"start\": [[70]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
16119501_1 | Baclofen withdrawal: a cause of prolonged fever in the intensive care unit. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[23]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Baclofen withdrawal\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Baclofen\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"prolonged fever\"]], \"start\": [[32]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
17596682_1 | Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complicating\"]], \"start\": [[49]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Interstitial pneumonitis and alveolar hemorrhage\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"rituximab\"]], \"start\": [[69]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"rituximab\"]], \"start\": [[69]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
11022272_4 | We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (Calsynar). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[135]], \"entity_id\": [\"T12\"]}, \"Effect\": {\"text\": [[\"several previous episodes of rhinitis, conjunctivitis and perspiration immediately\"]], \"start\": [[52]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"salmon calcitonin with nasal spray or intramuscular administration (Calsynar)\"]], \"start\": [[163]], \"entity_id\": [\"T10\"], \"Route\": {\"text\": [[\"nasal spray\"], [\"intramuscular\"]], \"start\": [[186], [201]], \"entity_id\": [\"T16\", \"T18\"]}, \"Drug\": {\"text\": [[\"salmon calcitonin\"]], \"start\": [[163]], \"entity_id\": [\"T19\"]}}, \"Subject\": {\"text\": [[\"a sixty years old woman\"]], \"start\": [[23]], \"entity_id\": [\"T13\"], \"Age\": {\"text\": [[\"sixty years old\"]], \"start\": [[25]], \"entity_id\": [\"T14\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[41]], \"entity_id\": [\"T15\"]}}}"
}
]
}
] |
15554737_1 | In this article, we describe another case of subcutaneous changes following repeated glatiramer acetate injection, presented as localized panniculitis in the area around the injection sites, in a 46-year-old female patient who was treated with glatiramer acetate for 18 months. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[66]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"subcutaneous changes\", \"presented as localized panniculitis in the area around the injection sites\"]], \"start\": [[45, 115]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"repeated glatiramer acetate injection\"]], \"start\": [[76]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"glatiramer acetate\"]], \"start\": [[85]], \"entity_id\": [\"T12\"]}, \"Route\": {\"text\": [[\"injection\"]], \"start\": [[104]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"a 46-year-old female patient\"]], \"start\": [[194]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"46-year-old\"]], \"start\": [[196]], \"entity_id\": [\"T10\"]}, \"Gender\": {\"text\": [[\"female\"]], \"start\": [[208]], \"entity_id\": [\"T11\"]}}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[231]], \"entity_id\": [\"T17\"]}, \"Subject\": {\"text\": [[\"a 46-year-old female patient\"]], \"start\": [[194]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"46-year-old\"]], \"start\": [[196]], \"entity_id\": [\"T10\"]}, \"Gender\": {\"text\": [[\"female\"]], \"start\": [[208]], \"entity_id\": [\"T11\"]}}, \"Treatment\": {\"text\": [[\"glatiramer acetate for 18 months\"]], \"start\": [[244]], \"entity_id\": [\"T18\"], \"Drug\": {\"text\": [[\"glatiramer acetate\"]], \"start\": [[244]], \"entity_id\": [\"T15\"]}, \"Time_elapsed\": {\"text\": [[\"18 months.\"]], \"start\": [[267]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
11033734_1 | Eighty-two patients with various malignancies who received imipenem/cilastatin 143 times for neutropenic fever between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"received\"]], \"start\": [[50]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"Eighty-two patients with various malignancies\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Population\": {\"text\": [[\"Eighty-two\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"various malignancies\"]], \"start\": [[25]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"imipenem/cilastatin 143 times for neutropenic fever\"]], \"start\": [[59]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"imipenem\"], [\"cilastatin\"]], \"start\": [[59], [68]], \"entity_id\": [\"T10\", \"T11\"]}, \"Disorder\": {\"text\": [[\"neutropenic fever\"]], \"start\": [[93]], \"entity_id\": [\"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"/\"]], \"start\": [[67]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"imipenem\"], [\"cilastatin\"]], \"start\": [[59], [68]], \"entity_id\": [\"T10\", \"T11\"]}}]}}"
}
]
}
] |
23624139_9 | The present report first highlights the potentially life-threatening side effects associated with over-the-counter NSAIDs during DDAVP replacement therapy for central DI. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated with\"]], \"start\": [[82]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"NSAIDs\"]], \"start\": [[115]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"NSAIDs\"], [\"DDAVP\"]], \"start\": [[115], [129]], \"entity_id\": [\"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[122]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"NSAIDs\"], [\"DDAVP\"]], \"start\": [[115], [129]], \"entity_id\": [\"T11\", \"T12\"]}}]}, \"Effect\": {\"text\": [[\"potentially life-threatening side effects\"]], \"start\": [[40]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
16623611_1 | Case report: lack of control of diabetes and weight gain in a patient on initiation and rechallenge of therapy with olanzapine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"initiation and rechallenge\"]], \"start\": [[73]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[60]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"diabetes\"], [\"weight gain\"]], \"start\": [[32], [45]], \"entity_id\": [\"T6\", \"T7\"]}, \"Treatment\": {\"text\": [[\"olanzapine\"]], \"start\": [[116]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"olanzapine\"]], \"start\": [[116]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
10030778_1 | Intravenous azithromycin-induced ototoxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[25]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"azithromycin\"]], \"start\": [[12]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"azithromycin\"]], \"start\": [[12]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"ototoxicity\"]], \"start\": [[33]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
24318743_14 | Orally delivered PXD showed no evidence of clinical activity, when combined with weekly AUC2-carboplatin in PROC. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"clinical activity\"]], \"start\": [[43]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"Orally delivered PXD\", \"weekly AUC2-carboplatin\"]], \"start\": [[0, 81]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"PROC\"]], \"start\": [[108]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"Orally\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"PXD\"], [\"AUC2-carboplatin\"]], \"start\": [[17], [88]], \"entity_id\": [\"T12\", \"T14\"]}, \"Freq\": {\"text\": [[\"weekly\"]], \"start\": [[81]], \"entity_id\": [\"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combined\"]], \"start\": [[67]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"PXD\"], [\"AUC2-carboplatin\"]], \"start\": [[17], [88]], \"entity_id\": [\"T12\", \"T14\"]}}]}, \"Negated\": {\"text\": [[\"no\"]], \"start\": [[28]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
18079582_3 | We report such a series of patients who had transient asymptomatic bradycardia after being treated with continuous infusion 5-FU. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[79]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"transient asymptomatic bradycardia\"]], \"start\": [[44]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"continuous infusion 5-FU\"]], \"start\": [[104]], \"entity_id\": [\"T5\"], \"Freq\": {\"text\": [[\"continuous\"]], \"start\": [[104]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"5-FU\"]], \"start\": [[124]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"infusion\"]], \"start\": [[115]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"a series of patients\"]], \"start\": [[15]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"a series\"]], \"start\": [[15]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
18854289_1 | Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[144]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"patients with multiple myeloma\"]], \"start\": [[147]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen\"]], \"start\": [[0]], \"entity_id\": [\"T13\"], \"Disorder\": {\"text\": [[\"multiple myeloma\"]], \"start\": [[161]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"bortezomib\"], [\"lenalidomide\"], [\"dexamethasone\"], [\"bortezomib\"], [\"dexamethasone\"]], \"start\": [[27], [38], [52], [73], [84]], \"entity_id\": [\"T16\", \"T17\", \"T18\", \"T19\", \"T20\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"/\"]], \"start\": [[37]], \"entity_id\": [\"T21\"]}, \"Drug\": {\"text\": [[\"bortezomib\"], [\"lenalidomide\"], [\"dexamethasone\"]], \"start\": [[27], [38], [52]], \"entity_id\": [\"T16\", \"T17\", \"T18\"]}}, {\"event_id\": \"E3\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"/\"]], \"start\": [[83]], \"entity_id\": [\"T22\"]}, \"Drug\": {\"text\": [[\"bortezomib\"], [\"dexamethasone\"]], \"start\": [[73], [84]], \"entity_id\": [\"T19\", \"T20\"]}}]}}"
}
]
}
] |
24318743_3 | Based on prior data suggesting that scheduling alterations of platinum would increase activity, the aim of the present study was to assess the potential therapeutic benefit of phenoxodiol (PXD), a novel biomodulator shown to have chemoresistance reversing potential, when combined with weekly AUC2-carboplatin in PROC patients. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"assess\"]], \"start\": [[132]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"phenoxodiol (PXD), a novel biomodulator shown to have chemoresistance reversing potential, when combined with weekly AUC2-carboplatin\"]], \"start\": [[176]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"phenoxodiol\"], [\"carboplatin\"]], \"start\": [[176], [298]], \"entity_id\": [\"T15\", \"T19\"]}, \"Disorder\": {\"text\": [[\"PROC\"]], \"start\": [[313]], \"entity_id\": [\"T16\"]}, \"Freq\": {\"text\": [[\"weekly\"]], \"start\": [[286]], \"entity_id\": [\"T18\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combined\"]], \"start\": [[272]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"carboplatin\"], [\"phenoxodiol\"]], \"start\": [[298], [176]], \"entity_id\": [\"T19\", \"T15\"]}}]}, \"Effect\": {\"text\": [[\"potential therapeutic benefit\"]], \"start\": [[143]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"PROC patients\"]], \"start\": [[313]], \"entity_id\": [\"T13\"]}}"
}
]
}
] |
8832451_3 | We also describe a new, noninvasive method to assess magnesium-induced neuromuscular block when curariform muscle relaxant was given simultaneously. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[63]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"curariform muscle relaxant was given simultaneously\"]], \"start\": [[96]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"magnesium\"], [\"curariform muscle relaxant\"]], \"start\": [[53], [96]], \"entity_id\": [\"T6\", \"T7\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"simultaneously\"]], \"start\": [[133]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"magnesium\"], [\"curariform muscle relaxant\"]], \"start\": [[53], [96]], \"entity_id\": [\"T6\", \"T7\"]}}]}, \"Effect\": {\"text\": [[\"neuromuscular block\"]], \"start\": [[71]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
1378497_2 | Our series of 3 patients supports a causal connection between bleomycin and scleroderma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"supports\"]], \"start\": [[25]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"3 patients\"]], \"start\": [[14]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"3\"]], \"start\": [[14]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"bleomycin\"]], \"start\": [[62]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"bleomycin\"]], \"start\": [[62]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"scleroderma\"]], \"start\": [[76]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
16404563_6 | In this paper, we report a patient with primary anti-phospholipid syndrome treated by corticosteroid, who developed disseminated nocardiosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[106]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[25]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"corticosteroid\"]], \"start\": [[86]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"corticosteroid\"]], \"start\": [[86]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"anti-phospholipid syndrome\"]], \"start\": [[48]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"disseminated nocardiosis\"]], \"start\": [[116]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
9052919_1 | Eye movement disorders in bone marrow transplant patients on cyclosporin and ganciclovir. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"on\"]], \"start\": [[58]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Eye movement disorders\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"bone marrow transplant patients\"]], \"start\": [[26]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"bone marrow transplant\"]], \"start\": [[26]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"cyclosporin and ganciclovir\"]], \"start\": [[61]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"cyclosporin\"], [\"ganciclovir\"]], \"start\": [[61], [77]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[73]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"cyclosporin\"], [\"ganciclovir\"]], \"start\": [[61], [77]], \"entity_id\": [\"T9\", \"T10\"]}}]}}"
}
]
}
] |
4025011_1 | Prolonged severe cholestasis induced by oxacillin derivatives. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[29]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Prolonged severe cholestasis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"oxacillin derivatives\"]], \"start\": [[40]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"oxacillin\"]], \"start\": [[40]], \"entity_id\": [\"T6\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[10]], \"entity_id\": [\"T7\"], \"value\": \"High\"}}"
}
]
}
] |
21881031_11 | Cisplatin was the common drug in the cases presented and therefore could be related to the INR elevations. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[76]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Cisplatin\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Cisplatin\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"the cases\"]], \"start\": [[33]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"INR elevations\"]], \"start\": [[91]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"could\"]], \"start\": [[67]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
17624096_1 | 5-Fluorouracil cardiotoxicity complicating treatment of stage IIB cervical cancer--case report. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complicating\"]], \"start\": [[30]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"5-Fluorouracil\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"5-Fluorouracil\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"cervical cancer\"]], \"start\": [[66]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"cardiotoxicity\"]], \"start\": [[15]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
17241588_1 | RESULTS: A clinical diagnosis of fixed drug eruption owing to use of the PDE5 inhibitor tadalafil (Cialis) was made. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"owing\"]], \"start\": [[53]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"fixed drug eruption\"]], \"start\": [[33]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"PDE5 inhibitor tadalafil (Cialis)\"]], \"start\": [[73]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"tadalafil\"]], \"start\": [[88]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
9719245_3 | Pancytopenia associated with 5-aminosalicylic acid use in a patient with Crohn's disease. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[13]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Pancytopenia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"5-aminosalicylic acid\"]], \"start\": [[29]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"Crohn's disease\"]], \"start\": [[73]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"5-aminosalicylic acid\"]], \"start\": [[29]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"a patient with Crohn's disease\"]], \"start\": [[58]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
12111771_2 | Fludarabine induced lung toxicity must be considered in all patients who develop unexplained lung disease while receiving fludarabine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[112]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"all patients who develop unexplained lung disease\"]], \"start\": [[56]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"lung disease\"]], \"start\": [[93]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"Fludarabine induced lung toxicity\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"fludarabine\"]], \"start\": [[122]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"fludarabine\"]], \"start\": [[122]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
8007037_1 | Although other nitrites induce methemoglobinemia, exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[135]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"methyl nitrite\"]], \"start\": [[62]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"methyl nitrite\"]], \"start\": [[62]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"occupational methemoglobinemia\"]], \"start\": [[144]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"appears to be\"]], \"start\": [[115]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
15694139_5 | We report four cases of sensorimotor axonal neuropathy in children aged 10-15 years, treated with thalidomide for myxopapillary ependymoma, Crohn's disease and recurrent giant aphthous ulceration. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[85]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"four cases\", \"children aged 10-15 years\", \"myxopapillary ependymoma, Crohn's disease and recurrent giant aphthous ulceration\"]], \"start\": [[10, 58, 114]], \"entity_id\": [\"T9\"], \"Population\": {\"text\": [[\"four\"]], \"start\": [[10]], \"entity_id\": [\"T16\"]}, \"Age\": {\"text\": [[\"10-15 years\"]], \"start\": [[72]], \"entity_id\": [\"T21\"]}}, \"Effect\": {\"text\": [[\"sensorimotor axonal neuropathy\"]], \"start\": [[24]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"thalidomide\"]], \"start\": [[98]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"thalidomide\"]], \"start\": [[98]], \"entity_id\": [\"T17\"]}, \"Disorder\": {\"text\": [[\"myxopapillary ependymoma\"], [\"Crohn's disease\"], [\"ecurrent giant aphthous ulceration\"]], \"start\": [[114], [140], [161]], \"entity_id\": [\"T18\", \"T19\", \"T20\"]}}}"
}
]
}
] |
20298401_9 | The patient died of respiratory failure after 8 days of steroid infusion and erlotinib discontinuation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[40]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"The patient\"], [\"The\"]], \"start\": [[0], [0]], \"entity_id\": [\"T6\", \"T15\"]}, \"Effect\": {\"text\": [[\"died of respiratory failure\"]], \"start\": [[12]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"8 days of steroid infusion and erlotinib discontinuation.\"]], \"start\": [[46]], \"entity_id\": [\"T9\"], \"Time_elapsed\": {\"text\": [[\"after 8 days\"]], \"start\": [[40]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"steroid\"], [\"erlotinib\"]], \"start\": [[56], [77]], \"entity_id\": [\"T12\", \"T14\"]}, \"Route\": {\"text\": [[\"infusion\"]], \"start\": [[64]], \"entity_id\": [\"T13\"]}}, \"Severity\": {\"text\": [[\"died\"]], \"start\": [[12]], \"entity_id\": [\"T10\"], \"value\": \"High\"}}"
}
]
}
] |
7962394_3 | Hypo-oestrogenic and anabolic/androgenic side-effects of danazol are well known by the gynaecologist and some of them are present in > 50% of patients being treated for endometriosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"side-effects\"]], \"start\": [[41]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Hypo-oestrogenic and anabolic/androgenic\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"danazol\"]], \"start\": [[57]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"danazol\"]], \"start\": [[57]], \"entity_id\": [\"T6\"]}, \"Disorder\": {\"text\": [[\"endometriosis\"]], \"start\": [[169]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
10656221_9 | We believe that this is the first description of acute hepatitis caused by an idiosyncratic adverse reaction to gliclazide or to one of its metabolites. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"idiosyncratic adverse reaction\"]], \"start\": [[78]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"acute hepatitis\"]], \"start\": [[49]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"gliclazide\"]], \"start\": [[112]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"gliclazide\"]], \"start\": [[112]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
15482394_4 | In view of our experience in the present case, it should be stressed that close monitoring of coagulation capacity is necessary in critically ill patients in order to avoid fatal haemorrhage after initiating warfarin therapy regardless of the dosage. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[191]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"initiating warfarin therapy regardless of the dosage\"]], \"start\": [[197]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"warfarin\"]], \"start\": [[208]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"haemorrhage\"]], \"start\": [[179]], \"entity_id\": [\"T4\"]}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[173]], \"entity_id\": [\"T7\"], \"value\": \"High\"}}"
}
]
}
] |
17352036_4 | We report a patient who developed acute pancreatitis during amiodarone therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[53]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"amiodarone\"]], \"start\": [[60]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[60]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"acute pancreatitis\"]], \"start\": [[34]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[10]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
9602881_1 | We report a 76-year-old man who developed an acute blistering eruption following high-dose penicillin treatment for pneumococcal septicaemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[32]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"76-year-old man\"]], \"start\": [[12]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"76-year-old\"]], \"start\": [[12]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[24]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"acute blistering eruption\"]], \"start\": [[45]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"high-dose penicillin treatment\"]], \"start\": [[81]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"penicillin\"]], \"start\": [[91]], \"entity_id\": [\"T9\"]}, \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[81]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"pneumococcal septicaemia\"]], \"start\": [[116]], \"entity_id\": [\"T11\"]}}, \"Severity\": {\"text\": [[\"acute\"]], \"start\": [[45]], \"entity_id\": [\"T12\"], \"value\": \"High\"}}"
}
]
}
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.